Related Experiment Video

Updated: Aug 8, 2026

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

[Targeting angiogenesis in oncology]

J Fayette1, J-C Soria, J-P Armand

  • 1Département de médecine, institut Gustave-Roussy, Villejuif, France. jfayette@9online.fr

Pathologie-Biologie
|June 7, 2006
PubMed

Insights

New drugs targeting tumor angiogenesis, the process of new blood vessel formation, are in development. By inhibiting key molecular mediators like VEGF, these therapies aim to reduce tumor size by causing neovessel death.

Area of Science:

  • Molecular biology
  • Oncology
  • Biochemistry

Context:

  • Tumor growth is critically dependent on angiogenesis, the formation of new blood vessels.
  • Tumor cells release growth factors, such as vascular endothelial growth factor (VEGF), to stimulate endothelial cells.
  • This process is a key target for anti-cancer drug development.

Purpose:

  • To review the molecular mechanisms of angiogenesis in tumor growth.
  • To describe various angiogenesis inhibitors currently in clinical development.
  • To highlight the diverse mechanisms of action of these anti-angiogenic compounds.

Summary:

  • Advances in biological understanding have elucidated the molecular pathways governing angiogenesis.
  • VEGF-mediated signaling activates endothelial cells, promoting neovascularization essential for tumor expansion.
  • Several drugs in clinical trials target these molecular mediators, aiming to induce neovessel death and reduce tumor mass.

Impact:

  • Provides a comprehensive overview of anti-angiogenic strategies for cancer therapy.
  • Highlights the potential of targeting tumor angiogenesis for effective cancer treatment.
  • Informs researchers and clinicians about the diverse landscape of angiogenesis inhibitors.

More Related Videos

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies09:03

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.